ARTICLE | Company News
Management tracks: Gilead's Riva leaving for Glenmark innovation business
March 6, 2019 12:32 AM UTC
Gilead EVP of Oncology Therapeutics Alessandro Riva is leaving the company to join Glenmark's innovation business as CEO, effective April 2. Gilead said it is seeking a replacement.
The news comes just days after Daniel O’Day officially became chairman and CEO of Gilead Sciences Inc. (NASDAQ:GILD) (see "O'Day's Expansive Task at Gilead")...